In terms of somatic DDR alterations, TP53 mutations are detected in 3–20% of prostate tumors at the time of diagnosis (primary disease) [30,31] and in up to 42% of advanced prostate tumors [32,33], correlating with high-grade disease, cancer relapse, castration resistance and metastasis [34,35]. This evidence concerns the gene TP53 and prostate neoplasm.